Save the Date: June 25, Newron Investor Day: Evenamide for poor responders and patients with treatment-resistant Schizophrenia, a Roadmap to Registration

SAVE THE DATE

June 25, 2024

Evenamide: Roadmap to Registration

Investor Day 2024

Join us for a deep dive into the unmet needs and new concepts for treating poor responders and patients with treatment-resistant schizophrenia with three of the world's leading experts in the fields of neuroscience and treatment-resistant schizophrenia:

Featured speakers to include:

• Anthony Grace, Ph.D., Distinguished Professor of Neuroscience, Professor of Psychiatry and Psychology
  University of Pittsburgh
• John Kane, M.D., Co-Director & Professor, Institute of Behavioral Science,
  Feinstein Institutes for Medical Research
  Professor of Psychiatry, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
• Stephen R. Marder, M.D., Daniel X. Freedman Professor of Psychiatry, Semel Institute of Neuroscience & Human Behavior
  Director, Section on Psychosis, UCLA Neuropsychiatric Institute
• Ravi Anand, MD, Chief Medical Officer Newron Pharmaceuticals

Tuesday, June 25, 2024

9-11amET /3-5pm CET

Convene, 530 Fifth Avenue

between 44th & 45th Street, New York City

For further information, or to register for the event, please contact:

Newron

Stefan Weber - CEO, [phone], [e-mail]

UK/Europe

Simon Conway / Ciara Martin / Natalie Garland-Collins, FTI Consulting, [phone], [e-mail]

Switzerland

Valentin Handschin, IRF , [phone], [e-mail]

Germany/Europe

Anne Hennecke / Caroline Bergmann, MC Services, [phone], [e-mail]

USA

Paul Sagan, LaVoieHealthScience, [phone], Ext. 112, [e-mail]

About evenamide

Evenamide, an orally available new chemical entity, specifically blocks voltage-gated sodium channels (VGSCs) and is devoid of biological activity at >130 other CNS targets. It normalizes glutamate release induced by aberrant sodium channel activity (veratridine-stimulated), without affecting basal glutamate levels, due to inhibition of VGSCs. Combinations of ineffective doses of evenamide and other APs, including clozapine, were associated with benefit in animal models of psychosis, suggesting synergies in mechanisms that may provide benefit in patients who are poor responders to current APs, including clozapine.

About Newron Pharmaceuticals

Newron (SIX: NWRN, XETRA: NP5) is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. The Company is headquartered in Bresso near Milan, Italy. Xadago®/safinamide has received marketing authorization for the treatment of Parkinson's disease in the European Union, Switzerland, the UK, the USA, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan and South Korea, and is commercialized by Newron's Partner Zambon. Supernus Pharmaceuticals holds the commercialization rights in the USA. Meiji Seika has the rights to develop and commercialize the compound in Japan and other key Asian territories. Newron is also developing evenamide as the potential first add-on therapy for the treatment of patients with symptoms of schizophrenia. For more information, please visit: www.newron.com